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Abstract
Objective
To determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for
neurologic conditions, into mature breast milk.
Methods
Breast milk samples were collected from 9 women with MS who received rituximab 500 or
1,000 mg intravenous once or twice while breastfeeding from November 2017 to April 2019.
Serial breast milk samples were collected before infusion and at 8 hours, 24 hours, 7 days, and
18–21 days after rituximab infusion in 4 patients. Five additional patients provided 1–2 samples
at various times after rituximab infusion.
Results
The median average rituximab concentration in mature breast milk was low at 0.063 μg/mL
(range 0.046–0.097) in the 4 patients with serial breast milk collection, with an estimated
median absolute infant dose of 0.0094 mg/kg/d and a relative infant dose (RID) of 0.08%
(range 0.06%–0.10%). Most patients had a maximum concentration at 1–7 days after infusion.
The maximum concentration occurred in a woman with a single breast milk sample and was
0.29 μg/mL at 11 days postinfusion, which corresponds with an estimated RID of 0.33%.
Rituximab concentration in milk was virtually undetectable by 90 days postinfusion.
Conclusions
We determined minimal transfer of rituximab into mature breast milk. The RID for rituximab
was less than 0.4% and well below theoretically acceptable levels of less than 10%. Low oral
bioavailability would probably also limit the absorption of rituximab by the newborn. In women
with serious autoimmune neurologic conditions, monoclonal antibody therapy may afford an
acceptable benefit to risk ratio, supporting both maternal treatment and breastfeeding.
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Neurologic diseases including multiple sclerosis (MS), neuro-
myelitis optica spectrum disorder (NMOSD), autoimmune
encephalitis, myasthenia gravis, and migraine commonly
affect women of childbearing age, and monoclonal antibody
therapies are becoming increasingly available for these
conditions.1–5 However, limited data on the safety of medi-
cations during breastfeeding force many women to choose
between treating their neurologic disease or breastfeeding
their infant, despite the many benefits of breastfeeding.6
Monoclonal antibodies are appealing options during breast-
feeding because immunoglobulin Gs (IgGs) are large mole-
cules with low expected breast milk transfer after the
colostrum phase, with IgA the main immunoglobulin in hu-
man breast milk.7,8 There have been recent efforts to bridge
the gap in safety data for monoclonal antibodies during
breastfeeding,9,10 given their widespread use in neurologic,
rheumatologic, gastrointestinal (GI), and oncologic diseases.
In fact, the American College of Rheumatology presented
guidelines in 2018 discussing use of biologics while breast-
feeding,11 and in 2019, the American Gastrointestinal Asso-
ciation recommended biologics can be continued while
breastfeeding.12 In neurology, there are limited data and no
guidelines for monoclonal antibody use during breastfeeding.
Rituximab is an anti-CD20 monoclonal IgG1 antibody used
widely for neurologic autoimmune conditions and is effective
and used off-label for MS and myasthenia gravis.13–15 Only
a single case report measured rituximab concentration in
breast milk, for a woman with vasculitis, and levels were re-
assuringly low (≤0.6 μg/mL). However, sample collection
occurred on days 7–10 after infusion, and thus, peak con-
centration and decline in concentration were not captured.16
Herein, we aimed to evaluate the transfer of rituximab into
mature breast milk in postpartum patients with MS.
Methods
Study design and population
In this prospective cohort, we enrolled women with MS re-
ceiving rituximab clinically while breastfeeding or shortly after
weaning and who were willing to provide breast milk samples.
All participants were enrolled in the University of California,
San Francisco (UCSF) pregnancy registry for women with
demyelinating diseases, which includes patients followed up at
the UCSF MS Center and women followed up at other
centers if they seek enrollment in the registry, often facilitated
by their neurologist. The samples included in this analysis
were collected from November 2017 to April 2019.
Patient demographics, medical history, and peripartum details
were obtained through questionnaires, interview, and review of
medical records. Medical records were reviewed to collect
demographic data, treatment history, rituximab infusion
date(s)/time and dose(s), and Expanded Disability Status
Scale (EDSS) score before pregnancy. Prospective ques-
tionnaires collected pregnancy information including treat-
ment before and during pregnancy, pregnancy complications,
delivery information, and breastfeeding status. Interview was
used to supplement missing information including breast-
feeding information and infusion dates as needed. Data from
all sites were collected in the same manner by the UCSF
study team after referral to the pregnancy registry by their
neurologist.
Standard protocol approvals, registrations,
and patient consents
The UCSF Institutional Review Board approved this study
(17–22422). Patients provided informed consent to enter the
study and provide breast milk samples.
Breast milk collection
Feasibility samples
To evaluate feasibility and validate rituximab concentration
assay techniques, we initially collected 1–2 breast milk sam-
ples from 4 mothers (5 samples total) within 2 weeks after 1
or 2 rituximab infusions of 500 or 1,000 mg intravenous (IV)
(feasibility samples).
Serial samples
We then systematically collected serial breast milk samples
preinfusion (drug-naive) and at 8, 24, and 48 hours as well as
at 7, 18–21, and 30 days after rituximab 500 or 1,000 mg
infusion once or twice when possible in 4mothers (1 of whom
had 2 samples as part of feasibility samples).
Delayed samples
In 2 cases, eligible patients were identified at a timeframe
more remote from their rituximab infusion, and to maximize
available data, delayed samples from these patients were col-
lected up to 90 days from infusion.
The feasibility, serial, and delayed samples were all assayed in
the same batch and are all reported to maximize data.
All samples included mature breast milk, which occurs be-
ginning 14 days postpartum, after the colostrum and transi-
tional phases. Mothers collected breast milk samples (2–5 cc)
by pumpingmilk from the breast into sterile freezer safe breast
milk bags (NUK brand). The samples were stored by mothers
Glossary
ASQ3 = Ages and Stages Questionnaire; AUC = area under the curve; CDC = Centers for Disease Control and Prevention;
EDSS = Expanded Disability Status Scale; GI = gastrointestinal; ICC = intraclass correlation coefficient; IV = intravenous;
NMOSD = neuromyelitis optica spectrum disorder;RID = relative infant dose;UCSF =University of California, San Francisco.
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at 4°C immediately after collection and then transported lo-
cally on dry ice (<1 hour) or shipped overnight in insulated
PolarTech shipping containers lined with ThermoSafe
PolarPacks to the UCSF, where they were stored at −80°C.
Samples were transported on dry ice (<1 hour) to Marin
Biologic Laboratories, Inc., for analysis.
Quantification of rituximab in breast milk
To determine the breast milk concentration of rituximab, sam-
ples were analyzed byMarin Biologic Laboratories (Novato, CA,
US) using the Eagle Biosciences rituximab ELISA kit. This
ELISA is based on a rituximab-specific mouse monoclonal an-
tibody. Standards and samples were incubated in the microtiter
plate coated with a capture antibody. After incubation, the wells
were washed, and a horseradish peroxidase-conjugated antihu-
man IgG monoclonal antibody was added that bound to ritux-
imab. After incubation, the wells were washed, and the bound
enzymatic activity was detected by addition of chromogen-
substrate. The color was proportional to the amount of ritux-
imab in the sample or standard; the optical density was
measured using a spectrophotometer at 450 nm. Rituximab
concentrations of samples were determined by using the
standard curve and measured in ng/mL and were then con-
verted to μg/mL for analyses and reporting for ease of
interpretation.
In an initial qualification experiment to test the ELISA kit, 3
standard curves were prepared with drug-naive milk
specimens using 3 different conditions (kit standard pre-
pared in dilution buffer, in neat naive milk, and in naive milk
diluted 1:10 in a dilution buffer). Recovery of the rituximab
standard was similar in all conditions. The method of
testing clinical samples neat or at various dilutions and
determining ng/mL values from the standard curve in kit
buffer was also qualified by testing 5 feasibility clinical
samples neat and at 1:1, 1:10, and 1:30 dilution in kit buffer,
with analysis against standard curves prepared in buffer in
neat milk or in 1:10 milk. Because there was no statistical
difference between the methods of analysis, the final ex-
periment testing concentrations reported in this study
tested the samples neat.
Two breast milk concentrations were measured on each
sample in duplicate, and the intraclass correlation coefficient
(ICC) was calculated to evaluate reproducibility. The 2 rep-
licates were averaged for the final breast milk concentration
for each sample.
Statistical analysis
For the 4 women who provided serial (at least 5) samples,
the breast milk concentrations of rituximab were analyzed
with pharmacokinetic methods using STATA 15 (College
Station, TX). The trapezoidal rule was used to calculate the
area under the breast milk concentration-time curves
(AUC) for each of these women. The average concentra-
tion of rituximab in breast milk (Cavg) was calculated by
dividing the AUC by the number of days from infusion at
the time of the last breast milk sample for each woman.
We also determined the maximum concentration (Cmax)
and the time of the maximum concentration for each
woman.
The absolute average and maximum rituximab dose to the
infant in a 24-hour period and the relative infant dose (RID)
were calculated using methods described by Bennett.17 The
actual maternal weight at the time or closely after the in-
fusion was used for each woman. Calculation of the absolute
average and maximum dose and the RID assumes the infant
will ingest approximately 150 cc/kg/d of breast milk over
a typical 24-hour period. The absolute average infant dose
over 24 hours is calculated by multiplying the Cavg by 150
cc/kg/d, whereas the maximum absolute infant dose is
calculated by multiplying Cmax by 150 cc/kg/d. The RID
estimates the infant’s exposure to rituximab as a percentage
of the maternal dose over a 24-hour period and is calculated
by taking the Cavg in mg/L, multiplying by 0.15 L/kg/d of
breast milk and by the maternal weight, and then dividing by
the maternal dose. The RID was also calculated using Cmax
to determine the maximum RID based on data collected. It
has previously been reported by Bennett17 that a RID less
than 10% is generally safe for an infant to breastfeed,
although toxicity of the specific drug should also be
considered.
Median and range were then calculated for these measures
across the women who provided serial samples. Although the
rituximab concentrations in the women who provided 1–2
samples (feasibility and delayed samples) were not included
in these calculations, they also contributed to our overall
understanding of rituximab transfer into breast milk and were
qualitatively compared with those of the women who pro-
vided serial samples.
Infant outcomes
Medical records were reviewed to identify birth outcomes,
infection, vaccination, growth, and developmental concerns in
the infants who breastfed while their mothers were receiving
rituximab from the time of birth to last well-child follow-up
available. Weight, length, and head circumference recorded in
medical records were compared with Centers for Disease
Control and Prevention (CDC) clinical growth charts and
reported as percentiles for age.18 The Ages and Stages
Questionnaire (ASQ3)19 was undertaken prospectively by
parents at 4, 8, and 12 months of age. The ASQ3 is a ques-
tionnaire that evaluates 5 domains of child development,
including gross motor, fine motor, communication, problem-
solving, and personal-social development. Each domain is
scored and categorized as “below cutoff,” “monitoring zone,”
or “above cutoff.” “Above cutoff” was considered normal be-
cause this indicates a child’s development is on schedule.
“Monitoring zone” means the child is close to the cutoff, and
providing learning materials and monitoring is suggested.
“Below cutoff” suggests professional assessment should be
completed.
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Data availability
Anonymized data are available to qualified investigators on
request for the purposes of replicating procedures or results
by contacting the corresponding author.
Results
Demographics and clinical characteristics
Nine women with MS who entered the UCSF pregnancy
registry for women with demyelinating diseases were
treated clinically with rituximab while breastfeeding or
shortly after weaning and agreed to provide breast milk
samples. All had relapsing remitting MS with relatively
mild disability (maximum EDSS of 2.0), with a mean age of
34 years and median disease duration of 4 years (table 1).
Four women had also received rituximab in the 6 months
before pregnancy, 1 received dimethyl fumarate before
pregnancy, and 1 received fingolimod before pregnancy,
followed by glatiramer acetate which was continued during
pregnancy. The other 3 women had not received disease-
modifying therapy in the 6 months before pregnancy. The
median time between delivery and rituximab treatment in
the samples provided was 6 months, with a range from 1.5
to 11 months. Most patients received a single rituximab
infusion of either 500 or 1,000 mg IV. One individual re-
ceived 500 mg IV twice (19 days apart) with samples
provided up to 19 days from the first infusion. Another had
previously received rituximab 1,000 mg twice 0.5 months
postpartum and provided samples after the second dose
of her second cycle of 1,000 mg twice at 7 months
postpartum.
Rituximab concentration in breast milk
The 9 women provided a total of 30 breast milk samples, with
4 patients providing at least 5 serial breast milk samples. The
ICC calculated with 2 replicates was excellent (0.997). Con-
centrations of rituximab in breast milk measured in all samples
are displayed in figure 1, and pharmacokinetic curves for the 4
patients with serial samples are shown in figure 2. The median
average rituximab concentration was low at 0.063 μg/mL
(range 0.046–0.097) in the 4 patients who provided serial
samples. Within these patients, the maximum rituximab
concentration occurred between 1 and 7 days from the in-
fusion, with a median maximum concentration of 0.074 μg/
mL (range 0.061–0.12). Based on the average concentration,
the median absolute 24-hour daily dose of rituximab was
0.0094 mg/kg/d, and the median RID was 0.08% (range
0.06%–0.10%) (table 2).
Among the patients who provided 1–2 breast milk samples
(feasibility and delayed samples), measured rituximab
concentrations were generally similar to those of patients
with serial samples apart from a single outlier with a rit-
uximab concentration of 0.29 μg/mL at 11 days post-
infusion (figure 1). This single outlier was a single sample
provided by a mother who received rituximab 1,000 mg at
9 months postpartum. To ensure that the RID was not
underestimated, this higher value was also used to calculate
the RID, and it remained low at 0.33%. One patient pro-
vided samples more remote from the rituximab infusion
at 60 and 90 days postinfusion. These values were re-
assuringly very low with a nearly undetectable level by 90
days. Rituximab levels in breast milk were not higher in
mothers who also received rituximab before pregnancy or
in the mother who received 1,000 mg twice instead of
a single infusion. Patient 3 (table 2 and figure 2C) had
increasing rituximab levels at the last sample on day 19
with her second dose of rituximab on that same day,
without capture of peak and decline after the second
infusion.
Infant outcomes
Of the 9 women, 5 continued to breastfeed after receiving
rituximab, whereas 4 discontinued breastfeeding before rit-
uximab infusion. Of the 5 mothers who breastfed after re-
ceiving rituximab postpartum, 3 also received rituximab
within the 6 months before pregnancy. Detailed information
is available for 4 infants who breastfed after their mothers
Table 1 Patient demographics and clinical characteristics
(n = 9)
Characteristic
Postpartum women
(n = 9)
Age, mean y (SD) 33.7 (3.2)
Weight, mean kg (SD) 73.9 (15.8)
Disease duration, median y (range) 4 (0–11)
MS subtype RRMS, n 9
EDSS, median (range) 0.0 (0.0–2.0)
Rituximab in 6 mo before pregnancy, n 4
Rituximab infusion to conception, median
mo (range)
2.5 (1.6–3.7)
Postpartum rituximab received, median mo
(range)
6 (1.5–11)
Rituximab dose, n
500 mg once 2
500 mg twice (2.7 wk apart) 1
1,000 mg once 5
1,000 mg twice (2 wk apart) 1
No. of breast milk samples provided, n
1 3
2 2
5 1
6 3
Abbreviations: EDSS = Expanded Disability Status Scale; RRMS = relapsing
remitting MS.
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received rituximab, whereas data were not available for the 1
other exposed infant (table 3). There were a few minor but
no serious infections. The infant exposed to rituximab
through breast milk earliest and with a higher total dose to
the mother had more infections (table 3, infant D), although
none were serious and all were common infections seen in
infancy. There were no preliminary concerns identified with
growth or development up to 8–12 months postpartum in
these infants, and routine vaccinations per CDC guidelines20
were given.
Figure 1 Rituximab concentrations in breast milk (n = 9)
Rituximab concentrations (μg/mL) in 9 patients up to 90 days from infusion of rituximab 1,000 or 500 mg intravenous once or twice. Lines connect samples
provided from a given individual. There was 1 outlier with a concentration of 0.29 μg/mL at 11 days postinfusion, although this level is still low.
Figure 2 Pharmacokinetic curves for rituximab concentration in breast milk for patients who provided serial samples (n = 4)
Rituximab concentrations (μg/mL) in 4 patients up to 30 days after infusion of rituximab 1,000mg IV once (A: patient 1; B: patient 2), 500mg IV twice day 0 and
19 (C: patient 3), or 500 mg IV once (D: patient 4). IV = intravenous.
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Discussion
In this prospective cohort study of postpartum women with
MS receiving rituximab, we observed very low transfer
of rituximab into mature breast milk. The average and
maximum concentrations of rituximab in breast milk were
reassuringly low and reached nearly undetectable levels by
60–90 days from the infusion. The median RID was 0.08%
and maximum RID was 0.10%, both less than the acceptable
value of less than 10%.17 Furthermore, the small amount of
rituximab reaching the breast milk is likely degraded in the
infant’s GI tract,8 with less than 25% of ingested IgG
reaching the stool and the remainder presumably diges-
ted.21 The neonatal Fc receptor may allow passage of these
undigested IgG molecules from the GI tract to circulation,22
and so a small amount of infant exposure cannot be
excluded.
The low concentrations of rituximab measured in mature
breast milk in our study were consistent with the low
concentration reported in the single case of vasculitis
treated with rituximab during breastfeeding.16 With serial
sampling of breast milk from 4 mothers, we were able to
calculate area under the breast milk concentration-time
curve, allowing calculation of the average concentration and
RID which were reassuring. Although the levels varied be-
tween patients, with a slightly higher maximum concen-
tration in 1 woman treated with 500 mg (figure 2C, patient
3) compared with others who received 1,000 mg rituximab,
the concentrations were overall quite similar and reassuringly
low. It is possible there may be minor interindividual vari-
ability in the pharmacokinetics and breast milk transfer of
rituximab.
Recent studies in inflammatory bowel disease evaluated
concentrations of other monoclonal antibodies in breast
milk, including tumor necrosis factor-alpha inhibitors, and
found reassuringly low peak concentrations.23,24 Natalizu-
mab, an IgG4 monoclonal antibody therapy for MS and
inflammatory bowel disease, represents 1 notable exception
because of more repeated dosing and the higher relative
proportion of IgG4 in mature breast milk than in
serum.25,26 Although low levels of natalizumab were
reported in breast milk in 2 patients,23 serial collection of
breast milk over 50 days from infusion in another single
patient suggested accumulation of natalizumab in breast
milk.27 By contrast, rituximab can be dosed once every
6–12 months and is an IgG1 subclass with a large molecular
weight (145 kD).28 IgG1 transfers in low levels into ma-
ture milk,26 which is consistent with our finding of lower
breast milk transfer of rituximab than that reported with
natalizumab.
Regarding pregnancy and neonatal outcomes with maternal
treatment with rituximab, a case series of 11 pregnancies in
women who received rituximab within 6 months of
Table 2 AUC, average concentration,maximumconcentration, and RID of rituximab in breastmilk among 4 patients with
serial samples
Parameters Patient 1 Patient 2 Patient 3 Patient 4 Median (range)
AUC0-Tmax, μg.d/mL 2.23 1.08 1.84 1.37 1.61 (1.08–2.23)
Tmax, d 30 21 19 30 25.5 (19–30)
Cavg, μg/mL 0.074 0.052 0.097 0.046 0.063 (0.046–0.097)
Cmax, μg/mL 0.083 0.065 0.12 0.061 0.074 (0.061–0.12)
Time of Cmax, d 7 2 1 7 4.5 (1–7)
Absolute infant dose by Cavg, mg/kg/d 0.011 0.0077 0.015 0.0068 0.0094 (0.0068–0.015)
Absolute infant dose by Cmax, mg/kg/d 0.012 0.0098 0.018 0.0092 0.011 (0.0092–0.018)
RID from Cavg, % 0.065 0.057 0.092 0.099 0.079 (0.057–0.099)
RID from Cmax, % 0.072 0.072 0.11 0.13 0.094 (0.072–0.13)
Rituximab dose, mg 1,000 × 1 1,000 × 1 500 × 2 500 × 1 1,000 (500–1,000)
Time of rituximab postpartum, mo 6 4 6 11 6 (4–11)
Maternal weight, kg 58.4 73.5 63.5 72.6 68.1 (58.4–73.5)
Breast milk samples, n 6 6 5 6 6 (5–6)
Timing of breast milk samples after
rituximab infusion
0, 8 h, 24 h, 7 d,
18 d, 30 d
0, 8 h, 24 h, 48 h,
7 d, 18 d
0, 8 h, 24 h, 7 d,
19 d
0, 8 h, 24 h, 7 d,
18 d, 30 d
Abbreviations: AUC = area under the drug-concentration-time curve in milk; Cavg = average drug concentration over the interval; Cmax = maximum drug
concentration measured; RID = relative infant dose; Tmax = maximum time of milk collection.
RID values are in bold because these are values of greatest importance.
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conception for MS and NMOSD, as well as a systematic
review of women treated for other conditions, did not
identify any major safety concerns.29 The patients included
in our study were clinically treated with rituximab while
breastfeeding, despite its off-label use in MS, likely based on
pregnancy safety data29 and the reassuring single case
report of a low breast milk rituximab concentration in
a patient treated for vasculitis.16 Because patients were
being treated clinically, this provided the opportunity to
measure the breast milk concentration of rituximab to help
guide future treatment decision-making in the postpartum
period.
Table 3 Outcomes for infants born to mothers treated with rituximab during breastfeeding
Characteristics Infant A Infant B Infant C Infant D
Time from last rituximab to
conception, mo
1.6 2.3 3.7 None
Time of postpartum
rituximab infusion, moa
2.6 4 6 0.5 and 7
DMT in pregnancy None None None Glatiramer acetate
Sex F F M F
Gestational age 38 wk 6 d 39 wk 4 d 41 wk 37 wk 3 d
Delivery method SVD SVD
assisted
SVD assisted SVD
Perinatal complications None None 2 BRUEb None
Breastfeeding mo after
postpartum rituximab
Discarded 2 mo then BF
4 mo
5 mo 2 mo 11.5 mo
Growth, timing 9 moc 9 moc 6 mo 1 wkc 5 moc
Weight, CDC percentile 50–75th 50–75th 75–90th 50th
Height, CDC percentile 50th 75–90th 75–90th 75–90th
Head circumference, CDC
percentile
75–90th 25–50th 90–95th 25–50th
Infections 2 wkd: Conjunctivitis
and dacryostenosis
7 moc:
Fever
5 mod: URTI and
otitis media
3 wkc: GERD and esophagitis; 2moc: URTI; 3moc: URTI and
diarrhea; 11 moc: Fever; 12 moc: URTI
Routine vaccinationse Complete Complete
except RV
Complete Complete
Development at well-child
visits
Normal Normal Normal Normal
ASQ3f 4 mod/8 moc 4 moc 4 mod/8moc 8 moc/12 moc
Gross motor Above/above Above Above/above Above/above
Fine motor Above/above Above Above/above Above/above
Communication Monitor/above Above Above/above Above/above
Problem-solving Above/above Above Above/above Above/above
Personal-social Above/above Above Above/above Above/above
Follow-up, mo 9 9 8 12
Abbreviations: ASQ3 = Ages and Stages Questionnaire; BF = breastfed; BRUE = brief resolved unexplained events; CDC = Centers for Disease Control and
Prevention; DMT = disease-modifying therapy; GERD = gastroesophageal reflux disease; RV = rotavirus; SVD = spontaneous vaginal delivery; URTI = upper
respiratory tract infection.
a 1,000 mg × 1 in infants A, B, C; 1,000 mg × 2 at 0.5 mo and 7 mo in infant D.
b 2 brief resolved unexplained events of color changes while breastfeeding during the first d of life, but was monitored with no additional complications.
c Time point after postpartum rituximab received by the mother and breastfeeding.
d Time point before postpartum rituximab received by the mother and breastfeeding.
e Vaccinations as per CDC guidelines20 up to 9 mo of age include diphtheria, tetanus, and acellular pertussis (DTaP), Haemophilus influenzae type b (Hib),
pneumococcal conjugate (PCV13), inactivated poliovirus (IPV), hepatitis B (HepB), Rotavirus (RV1 or RV5), and influenza (IIV). Only infant D had reached the age
at which CDC recommends live vaccination against measles, mumps, and rubella (MMR), and this was given routinely. None had yet received varicella
vaccination because of their age.
f The ASQ3 evaluates 5 domains of child development: gross motor, fine motor, communication, problem-solving, and personal-social development. Each
domain is scored and categorized as “below cutoff,” “monitoring zone” (Monitor), or “above cutoff” (Above). “Above cutoff” means child development is on
schedule in the given domain. Eight-month ASQ3 is missing for infant B and 4-month ASQ3 is missing for infant D.
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Four mothers in our cohort breastfed after receiving rituximab
and provided growth, development, and medical records for
their infants, which demonstrated no serious infections and
normal growth and development in these infants followed up
to 8–12 months of age. Even the infant whose mother re-
ceived the highest total dose of rituximab early in the post-
partum period and who experienced the most infections was
well within the normal range of expected infections.30 Un-
fortunately, the small sample size and lack of a comparison
group precluded rigorous determination as to whether the
number of infections differed from expected. The effect of
postpartum rituximab timing and dose on infant outcomes
requires further study.
Limitations of this study include the relatively small number
of breast milk samples, although collection of serial milk
samples in 4 women did allow calculation of fairly consistent
AUC and RID. Unfortunately, serial breast milk collection at
the preferred time points was not available in all treated
women because data were collected during real-world use of
rituximab and not all participants were identified at the time of
rituximab treatment. In addition, we were unable to capture
the declining concentration of rituximab over time after a cy-
cle containing 2 infusions (patient 3) because of a lack of
sample collection after the second infusion. There were also
limited safety data in infants who continued to breastfeed after
rituximab treatment, with a relatively short follow-up in 4
infants. Unfortunately, blood samples from infants who
breastfed after their mothers received rituximab were not
available, so we could not assess rituximab concentration or
the biological effect of any possible rituximab exposure in the
infants, such as blood counts, CD19+ B cell counts, or re-
sponse to vaccination.
We expect that our findings would generalize to the use of
rituximab more broadly during breastfeeding; however,
some special cases must be considered. Maternal complica-
tions such as mastitis might allow greater transfer of large
molecules such as rituximab into breast milk.7 Our findings
may also not apply to breast milk in the first 14 days of life,
given the differences in the contents of colostrum and
transitional milk compared with mature breast milk. Finally,
in preterm infants, gut immaturity could affect absorption of
rituximab.
Further studies are required to evaluate the long-term infant
safety of rituximab treatment during breastfeeding, including
evaluation of the biological effect on lymphocyte subsets and
response to vaccination. Further study is also required to
understand whether maternal treatment with rituximab alters
the composition of breast milk because IgA is a major im-
munologic component of breast milk,8 and immunoglobulins
may be depleted with long-term rituximab treatment.31 It is
also not known whether the neonatal gut microbiome could
be affected by rituximab exposure in breast milk. Ocrelizumab,
another anti-CD20 monoclonal antibody that is Food and
Drug Administration-approved for MS, is also an IgG1
molecule of the same molecular size as rituximab (145
kDa),32 and therefore, we would expect similarly low ocreli-
zumab transfer into breast milk. To investigate this, our on-
going registry efforts will enable direct measurement of
ocrelizumab concentration in breast milk.
Altogether, our findings suggest that at least in the mature
milk phase in term infants, a single rituximab infusion results
in a RID in breast milk of less than 0.4% in all cases, which is
far less than the commonly accepted threshold of 10%. These
findings are appealing for women with a higher risk of disease
activity in the postpartum state (such as MS or NMOSD
relapse, which may be associated with disability progression,33
and refractory autoimmunemyasthenia gravis or autoimmune
encephalitis). In individual cases, the significant benefit of
maintaining neurologic stability in the mother with the help of
monoclonal antibodies could offset theoretical risks to the
infant, allowing both mother and infant to benefit from
breastfeeding.6 Areas requiring further study include evalu-
ating drug concentrations and lymphocyte counts in infants
exposed to drug-containing breast milk and studying longer-
term developmental data in these infants. Larger prospective
registry studies are ongoing.
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